Core Viewpoint - Samsung Medical achieved overseas revenue of 1.495 billion yuan in the first half of the year, representing a year-on-year growth of 51% [1] Group 1: Overseas Expansion - The company made significant breakthroughs in key overseas markets including Europe, the Middle East, and Latin America, with initial orders secured in Saudi Arabia, Mexico, Greece, and Brazil [1] - In the first half of 2025, the company also secured initial orders in Hungary, Romania, and Kyrgyzstan [1] - The company is focusing on high-end products and emerging markets, strengthening its presence in North America and Africa [1] Group 2: Local Operations and Support - The company is enhancing its localized operations by establishing a new sales company in Hungary, which will provide strong support for its overseas distribution business [1] Group 3: Order Backlog - The total order backlog for the company reached 17.632 billion yuan, reflecting a year-on-year increase of 18.39% [1] - The overseas distribution order backlog amounted to 2.182 billion yuan, showing a substantial year-on-year growth of 123.96% [1] Group 4: Investment Rating - Given the high growth in overseas orders and the company's leading position domestically, an investment rating of "Buy" has been assigned [1]